Recursion Pharmaceuticals (RXRX) Cash & Current Investments (2020 - 2025)
Recursion Pharmaceuticals' Cash & Current Investments history spans 6 years, with the latest figure at $747.9 million for Q4 2025.
- For Q4 2025, Cash & Current Investments rose 25.19% year-over-year to $747.9 million; the TTM value through Dec 2025 reached $747.9 million, up 25.19%, while the annual FY2025 figure was $747.9 million, 25.19% up from the prior year.
- Cash & Current Investments reached $747.9 million in Q4 2025 per RXRX's latest filing, up from $663.0 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $747.9 million in Q4 2025 to a low of $219.1 million in Q1 2021.
- Average Cash & Current Investments over 5 years is $490.5 million, with a median of $489.8 million recorded in 2024.
- Peak YoY movement for Cash & Current Investments: surged 169.75% in 2022, then plummeted 36.87% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $516.6 million in 2021, then grew by 6.7% to $551.2 million in 2022, then fell by 28.37% to $394.8 million in 2023, then soared by 51.32% to $597.4 million in 2024, then grew by 25.19% to $747.9 million in 2025.
- Per Business Quant, the three most recent readings for RXRX's Cash & Current Investments are $747.9 million (Q4 2025), $663.0 million (Q3 2025), and $528.2 million (Q2 2025).